Search

Memorial Sloan Kettering’s Vivian Strong, MD, FACS, addressed peers from around the world in May 2025 at the 16th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global Fight for Innovation, the U.S. Perspective,” as the meeting’s Jin Pok Kim Lecturer.

… Thursday, May 8, 2025 Memorial Sloan Kettering’s  Vivian Strong, MD, FACS , addressed peers from around the world in May 2025 at the 16 th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global

The first large study of its kind has found that having a healthy microbiota before starting the process of a bone marrow transplant using a patient’s own cells (autologous) leads to fewer complications after the procedure.

… Thursday, March 18, 2021 A patient’s health after a stem cell or bone marrow transplant (BMT) can depend on the bacteria in their gut. The trillions of microorganisms living there are also known as the microbiota. They can be damaged or wiped out by cancer treatments, leaving patients with severe intestinal

In a study published in the New England Journal of Medicine (NEJM), an MSK team report that they have found what enables cancer cells to become resistant to the experimental drug pirtobrutinib.

… Thursday, February 24, 2022 Since the first targeted therapies for blood cancer were developed more than 20 years ago, doctors and scientists have observed that many patients who respond well to these drugs initially end up developing resistance to them over time. There is an assumption among scientists

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

… Wednesday, August 30, 2017 Summary A novel form of immunotherapy called CAR T is now an FDA-approved option for people with acute lymphoblastic leukemia (ALL) that has stopped responding to chemotherapy. Our scientists played several key roles in CAR T cell therapy development. In what is being hailed

Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program. MSK physicians and scientists are involved in notable research to be presented at the meeting.

… Wednesday, May 27, 2020 Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program . The online meeting will provide an engaging lineup of scheduled and on-demand scientific content including a plenary session

The FDA has granted full approval to the targeted therapy selpercatinib (Retevmo®) for treating thyroid cancers that have certain changes in a gene called RET. Learn about MSK’s role in the development of this drug and about how patients may benefit.

… Wednesday, July 10, 2024 On June 12, 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy  selpercatinib (Retevmo ® ) for treating adult and pediatric patients 2 years and older with advanced or metastatic  thyroid cancers that have certain changes in a gene called

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

… Wednesday, January 10, 2024 Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to

Obtenga más información sobre el nuevo fármaco aprobado por la FDA, repotrectinib (AugtyroTM), que ataca las fusiones de ROS1 en el cáncer pulmonar y otros tipos de cáncer.

… Wednesday, January 10, 2024 Ingrid Adams, que ahora tiene 68 años, ha estado lidiando con el cáncer pulmonar metastásico durante más de una década. El tratamiento estándar, que incluye quimioterapia y radioterapia , mantuvo su enfermedad bajo control por un tiempo, pero el cáncer continuó diseminándose

Learn what can be done for patients like Stephanie Soto-Vega who confront financial hardships caused by cancer.

… Thursday, April 10, 2025 It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried

Meet a few of our brave and determined young patients who are thriving after receiving treatment at MSK.

… Friday, October 1, 2021 Ending cancer treatment is an exciting yet tricky transition for adolescents and young adults. But MSK keeps a close eye on these survivors as their physical, emotional, and social needs change over time. There are three survivorship clinics — each tailored to a specific age group